Anti-Neprilysin Market To Surpass US$ 1,665.72 Million By 2027 - Coherent Market Insights

1. ANTI-NEPRILYSIN MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Anti-Neprilysin Market - Overview Global Anti-Neprilysin Market, by Drug Type (Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others), by Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,160.01 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights. Anti-Neprilysin Market - Impact of Coronavirus (Covid-19) Pandemic Cardiac diseases are one of the leading causes of death worldwide so the demand for anti- neprilysin drugs has slightly reduced but this COVID-19 pandemic has not negatively impacted anti-neprilysin market. There is no reduction in the cases of heart failures, as COVID-19 affects the cardiac system in the end stage of COVID-19 infection. The lockdown policies in different countries have resulted in reduction in the supply of anti-neprilysin drugs, which is expected to affect the patients with cardiac conditions. The increasing number of product approvals and launches, adoption of anti-neprilysin drugs, and distribution agreements among key players are the major factors that are expected to drive growth of the anti-neprilysin market during the forecast period. Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/anti- neprilysin-market-4164 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION The rising adoption of anti-neprilysin drugs is expected to boost growth of the anti-neprilysin market during the forecast period. For instance, in June 2016, an analysis published in JAMA Cardiology found that timely and wide adoption of Entresto (sacubitril/valsartan) by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than 28,000 deaths each year in the U.S. alone. This analysis is based on the results of PARADIGM-HF trails on heart failure statistics, is the first to quantify the possible impact of Entresto's potential benefit in reducing death. Furthermore, the study suggests that delaying routine use of Entresto in clinical practice could have a substantial negative effect on patients, given the expected risk-benefit profile, as it could result in failure to prevent tens of thousands of deaths. These findings demonstrate the significant survival benefits Entresto could offer to those living with HFrEF if patients in the group defined by the authors were given access to treatment. The launch of new advanced anti-neprilysin drugs in the market is expected to contribute significantly to the anti-neprilysin market growth. For instance, in January 2016, Novartis International AG announced the launch of Entresto (sacubitril/valsartan) in the U.K. Entresto (sacubitril/valsartan) was approved in Europe in November 2015 to treat patients with heart failure and reduced ejection fraction, a condition where the heart muscle does not contract effectively and less oxygen-rich blood is pumped out to the body. The drug offers a novel dual mechanism of action to reduce the strain on the failing heart. Request a Sample copy of this reports : https://www.coherentmarketinsights.com/insight/request-sample/4164 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Browse 32 Market Data Tables and 34 Figures spread through 168 Pages and in-depth TOC on Anti-Neprilysin Market, by Drug Type (Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others), by Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027" For instance, in November 2016, Laboratorios Farmacéuticos Rovi, S.A. announced that it signed an agreement with Novartis Farmacéutica, S.A. (subsidiary of Novartis in Spain) to market Neparvis (sacubitril/valsartan) in Spain, which corresponds to Entresto of Novartis. Under this marketing agreement, ROVI takes the promotion and distribution rights of Neparvis in the Spain, a medicine indicated for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction (the proportion of blood leaving the heart). Key Takeaways of the Anti-Neprilysin Market: The anti-neprilysin market is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027), owing to the increasing number of product approvals and launches by key players Among type, the Sacubitril segment is expected to hold a major revenue share in 2027, owing to increasing R&D activities and product launches, which in turn can increase demand for anti- neprilysin drugs. Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4164 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved